Xenon Pharmaceuticals XENE Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's additional paid-in capital?
- Xenon Pharmaceuticals (XENE) reported additional paid-in capital of $264.88M in Q1 2026.
- How has Xenon Pharmaceuticals's additional paid-in capital changed year-over-year?
- Xenon Pharmaceuticals's additional paid-in capital increased by 27.1% year-over-year, from $208.46M to $264.88M.
- What is the long-term trend for Xenon Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's additional paid-in capital has grown at a 38.1% compound annual growth rate (CAGR), from $45.36M to $228.23M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.